Vectors and methods for genetic immunization

Inventors

Williams, James A.

Assignees

Aldevron LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9737620-B2

Patent

Publication Date

2017-08-22

Expiration Date


Abstract

Improved DNA vaccine plasmids are disclosed that contain novel immunostimulatory RNA compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short RNA based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation. These vectors are utilized in immunization to elicit improved immune responses or therapy to induce type 1 interferon production.

Core Innovation

The composition comprises an antibiotic marker-free, covalently closed, super-coiled DNA replicon containing a gene of interest. This replicon integrates an RNA-OUT antisense RNA gene sequence containing an internal insertion sequence 10-derived portion, an RNA-OUT promoter sequence, a portion complementary to an RNA-IN gene sequence, and a terminator sequence. The construct provides a selection system for recombinant replicon maintenance without conventional antibiotic resistance markers and supports sucrose counterselection compatibility across differing cassette orientations.

The replicon optionally incorporates a promoter operably linked to the gene of interest, such as a chimeric promoter, along with a promoter modification configured to increase expression. Structural refinements further encompass immunostimulatory RNA elements, including VARNA or eRNA, and backbones containing a mitochondrial R-region. These configurations retain antigen expression and RIG-I activation comparable to kanamycin-resistance controls while supporting vector architectures for recombinant expression systems.

Claims Coverage

The claim coverage comprises six inventive features directed to an antibiotic marker-free DNA replicon composition and specific structural configurations thereof.

RNA-OUT and gene-of-interest replicon composition

The independent claim covers an antibiotic marker-free, covalently closed, super-coiled DNA replicon comprising a gene of interest operably linked to an RNA-OUT antisense RNA gene sequence containing an internal insertion sequence 10-derived portion, an RNA-OUT promoter sequence, a portion complementary to an RNA-IN gene sequence, and a terminator sequence, with at least 90% sequence identity to SEQ ID NO: 15.

Promoter linked to the gene of interest

A dependent claim specifies that the replicon includes a promoter comprising SEQ ID NO: 6 operably linked to the gene of interest.

VARNA element

A dependent claim specifies that the replicon further comprises a VARNA element.

Immunostimulatory RNA element

A dependent claim specifies that the replicon further comprises at least one immunostimulatory RNA element.

Specified RNA-OUT sequence

A dependent claim specifies that the RNA-OUT antisense RNA gene sequence comprises SEQ ID NO: 15.

Expression-increasing promoter modification

A dependent claim specifies that the RNA-OUT antisense RNA gene comprises a promoter sequence modified to increase expression.

In summary, the claims cover an antibiotic marker-free replicon composition utilizing an RNA-OUT antisense sequence alongside specific promoter, regulatory, and immunostimulatory elements.

Stated Advantages

The RNA-OUT marker supports sucrose-based selection without an antibiotic marker.

The RNA-OUT marker is compatible with plasmid expression and production, providing robust selection across differing cassette orientations.

RNA-OUT plasmids retain antigen expression and RIG-I activation comparable to kanamycin-resistance controls.

The NTC7382 chimeric promoter is reported to increase expression relative to a CMV promoter.

The eRNA-containing vectors and mitochondrial R-region-containing backbones are reported to enhance interferon signaling and anti-HA immune responses.

Documented Applications

An antibiotic marker-free DNA vaccine plasmid containing a gene of interest.

Vaccine and gene-therapy applications for vectors encoding immunostimulatory RNA.

Expression-vector architectures including HA constructs and eRNA-containing vectors associated with anti-HA immune responses.

An RNA-OUT/RNA-IN selectable-marker region used for increasing plasmid yield during fermentation.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.